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Abstract
Intraspinal stem cell (SC) transplantation represents a new therapeutic approach for amyotrophic lateral sclerosis (ALS)
clinical trials.There are considerable difficulties in designing future efficacy trials, some related to the field of ALS and some
that are specific to SCs or the mode of delivery. In October 2015, the most controversial points on SC transplantation were
addressed during an international workshop intended to bring together international SC and ALS researchers in a public
discussion on a topic for which expertise is limited. During the meeting, a discussion was started on the basic structure of
the ideal clinical trial testing the efficacy and safety of SC transplantation. The current document includes a number of
consensus points reflecting the design of phase II/III clinical trials.
KeyWords: ALS, clinical trials, stem cells, transplantation
Introduction
Our knowledge on the molecular basis of amyo-
trophic lateral sclerosis (ALS) has significantly
progressed over the past few years; however, such dis-
coveries have not yet translated into new therapeutics.
A critical analysis of the failure of clinical trials of
proposed disease-modifying drugs in the past half-
century shows potential methodological reasons
that account for these negative results [1]. With the
advancement of stem cell (SC) technology, clinical trials
have been proposed as a novel therapeutic approach.
However, when we consider the use of SCs for treat-
ment, the level of complexity of designing SC clinical
trials is further increased by the extreme physiologi-
cal heterogeneity of these cells, limited knowledge about
optimal dosing schedule, uncertainty about the proper
way of delivery, need of immunosuppression, high
trial costs and ethical concerns. Clinical trials for
Parkinson disease that used primary fetal tissue have
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demonstrated, although with controversial results, that
fetal neural SCs could be suitable for neurodegenerative
diseases [2]. Recent in vivo studies have shown that
transplanted neural stem/precursor cells display good
survival and integration capacity into the damaged brain
parenchyma while also eliciting putative therapeutic
effects in different pathological conditions [3,4]. In these
studies, in addition to integration and differentiation
into neurons, astrocytes and oligodendrocytes, trans-
planted neural stem cells (NSCs) exerted their beneficial
effects through an immunomodulatory action involv-
ing both innate and adaptive (local versus systemic)
immune responses (e.g., microglial and astroglial scar
reduction,T-lymphocyte inhibition), as well as secre-
tion of trophic factors and cross correction of missing
enzymatic activities.
Intraparenchymal injection has been the method
of choice for most clinical studies. Local injections of
SCs have the obvious advantage of placing the cells
close to their therapeutic target and favor the diffu-
sion of trophic and immunomodulatory factors to both
the latter and the surrounding glia, thereby enhanc-
ing the likelihood of accomplishing therapeutic effects.
Preclinical studies in ALS animal models have clearly
demonstrated that SC transplantation in critical regions
of the spinal cord involved in crucial functions such
as respiratory capacity or the control of limb move-
ments offer the most significant clinical benefit [5,6].
Chronic inflammation plays an important role in ALS.
A most important therapeutic potential of SCs relies
on their ability to regulate inflammation and to empower
resident cells to facilitate tissue repair through en-
dogenous stem cell activation or environment
modulation. Both neural precursor cells [7] and mes-
enchymal stem cells (MSCs) [8] promote “bystander”
immunomodulation because they can release soluble
molecules and express immuno-relevant receptors that
are able to modify the inflammatory environment.
MSCs were found to attenuate neuroinflammation in
SOD1G93A transgenic mice [9,10].
The first U.S. Food and Drug Administration and
Italian Institute of Health–approved cell therapy trials
for ALS, based on the transplantation of human neural
progenitors cells (hNPC), were completed without sig-
nificant side effects [11,12]. However, substantial
challenges must be addressed and resolved to advance
the use of SC transplantation in efficacy trials for ALS.
We discuss the most controversial points addressed
during an international workshop intended to bring
together international SC and ALS researchers in a
public discussion of a topic on which expertise is limited.
During the meeting, a discussion was started on the
basic structure of the ideal clinical trial testing the ef-
ficacy and safety of intraspinal SC transplantation.The
current document includes a number of consensus
points reflecting the design of phase II/III clinical trials.
What have we learned from the first generation
of clinical trials of intraspinal stem cell
transplantation?
Few studies have addressed the safety of intraspinal
SC transplantation in small phase I/II clinical trials
[11–15].The most consistent results of the first phase
I clinical trials indicate that ALS patients tolerate the
surgical procedure and that the intraparenchymal de-
livery of the cells into the spinal cord is safe in expert
hands. Surgery was uncomplicated in most patients,
and few side effects were reported. In all published
trials, the most common negative event was tran-
sient pain in the surgery site.The atrophic spinal cord
of ALS patients is capable of tolerating up to at least
3 mL of cell suspension and 20 sites of injection at
all segments (cervical, thoracic, and lumbar) [13,14].
Both bone marrow SCs (MSCs and hematopoietic
SCs) and fetal NSCs have shown no abnormal growth
or tumor formation even in the long term up to 9
years for bone marrow SCs and 2 years for NSCs
[12]. In all clinical trials, the risk of teratogenicity
have been reduced with the administration of plu-
ripotent SCs or by differentiating SCs in vitro into
postmitotic phenotypes before administration [13].
Post mortem analysis showed the integrity and
survival of the grafted cells up to 2.5 years post-
transplantation [15,16]. Secondary proliferative lesions
have been reported after SC transplantation in the
context of SC tourism [17]. All published studies dem-
onstrated no acceleration in the course of the disease
due to the treatment.These results are not definitive
but provide clear signals that cellular grafting is fea-
sible and relatively safe in ALS patients and support
moving towards efficacy trials.
Translation into phase II/III clinical trials:
barriers and challenges
Patients selection
In phase I clinical trials, the primary aim is to assess
safety using a risk escalation paradigm [18]. Invasive
procedures, in fact, can generally be justified in pa-
tients with significant disability to be later extended
to less severely affected patients. In phase II/III clin-
ical trials, more restrictive inclusion/exclusion criteria
should be adopted to reduce the heterogeneity of
disease progression. Similar to pharmacological trials,
the maximum disease duration for the inclusion is pro-
posed to be 2 years from symptom onset with a
maximum age of 65 years (range: 18–65 years).Younger
patients might benefit more than older patients as also
evidenced in Parkinson disease [19].The cells, in fact,
should survive and integrate well in the adult brain
and spinal cord; however, the supportive host envi-
ronment starts to decline in aged individuals. Moreover
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the central nervous system shows a lower degree of
plasticity in older subjects.
Because early efficacy trials with SC transplanta-
tion face the need to establish a biological response
with a small number of subjects in a short time, a
key issue is to select homogeneous patients with
respect to the natural history of the disease (e.g., by
including patients with a similar progression of the ALS
Functional Rating Scale–revised [ALSFRS-R] and
forced vital capacity (FVC) in the 3–6 months before
the intervention) to differentiate patients with rapid
or slow disease progression. No definite position on
the inclusion of patients with focal variants such as
flail arm or flail leg was reached.
Global assessment for clinical trial entry should be
the ALS-FRS-R scale. Another recommended param-
eter is FVC with, the optimal indicated value being>70%
of predicted normal. However, an anaesthesiologist
should be also consulted to predict risk.
Trial outcomes
Patient selection is also intimately connected to study
end points. As the focus of clinical trials advances from
safety to efficacy, study hypotheses focus on demon-
strating significant delay or reversal of the progression
of the disease as well as possibly the improving the
pathophysiological targets defined from preclinical sup-
porting data. Defining the underlying mechanisms of
therapeutic action may contribute to accurate clini-
cal end-point selection and detection of appropriate
biomarkers for treatment response. At present, there
are no validated markers of the biological activity of
the cells and of therapeutic efficacy in ALS.The sug-
gested biomarkers of efficacy are positron emission
tomography (i.e., with [11C]PBR28] and [18F]-
FDG) and cerebrospinal fluid markers (cytokines,
neurofilament light protein, growth factors such as
GDNF). The use of neuroimaging such as magnetic
resonance imaging and diffusion tensor imaging in
transplanted areas are strongly encouraged for safety
monitoring. Multiple biomarkers should be used for
a phase II trial and a single end point for phase III
(i.e., quality of life, FVC, muscle strength, time to death
or tracheotomy) usually from discussion with regu-
latory agencies (U.S. Food and Drug Administration/
European Medicines Agency).The optimal assessment
parameters include ALSFRS-R and handgrip strength.
The Motor Unit Number Index or the Medical Re-
search Council score, might be also considered.
Individual “hard” end points, however, require large
trials and lack statistical power when insufficient
numbers of patients are included. For example, we
know that to show a 30% treatment effect slowing
ALSFRS-R, we need 400 subjects to enroll in the trial.
For 40% slowing, we need 200 subjects. This large
number of subjects might represent an impediment
for the increasing financial cost needed for funding
large SC clinical trials and the organizational diffi-
culties to perform a multicenter surgical trial.
Composite end points (biological and functional) might
provide an acceptable alternative to assess the clini-
cal effect of cell intervention [1].
Randomization
Assessing treatment effects by change over time in in-
dividual patients with defined clinical and functional
status and well-defined natural history without the use
of placebo controls may be of use in early phase II
studies. The value of including only historical con-
trols remains controversial, and most experts agree that
placebo-controlled studies are mandatory to test ef-
ficacy and that a sham arm is needed in phase III trials.
The inclusion of sham controls in later-phase efficacy
trials is in fact obligatory to distinguish potential effects
attributed to placebo, surgery, or the cell therapy as
clearly evidenced in clinical trials with SC transplan-
tation in Parkinson disease [20] and chronic stroke
[21]. However, the risks of a sham surgical procedure
are higher than a placebo in a medical trial and must
be minimized. Parameters of the intervention such as
dose, surgical technique, and time and procedure of
anesthesia will ideally need to be optimized before in-
cluding a sham arm. Multi-arm, dose selection phase
IIb studies should be designed to identify the optimal
number of cells before embarking on phase III trials.
The control group should ideally undergo proce-
dures that are identical in every respect and have
delivery of inert cells. A sham-operated group in-
jected with vehicle only could also be included to
introduce a more basic level of controls. Ethical and
cultural considerations, however, might be an obsta-
cle. The risks of sham procedures must be balanced
against scientific value. In addition, patients’ denial
of sham procedures may compromise recruitment and
be in itself a source of bias [22].
One way of addressing this issue is to use an uneven
randomization scheme, which assigns a higher number
of active to placebo subjects (i.e., 2:1, 3:1). The trial
should be a double-blind trial (i.e., neither the sub-
jects nor the investigators, including the surgeon, know
who is in the experimental or control arms. Because
of the dramatic course of the disease, the possibility
of switching controls to treatment should be consid-
ered if the approach is clearly beneficial in experimental
group.
Immunosuppression
The decision to consider immunosuppression is
based on a number of factors, including whether
the cellular product is autologous or allogeneic.
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Immunosuppression is indicated when using allo-
genic cells, but at present, it is unclear how long the
treatment should continue.The decision is related to
the type of cells (SCs versus progenitor cells). However,
the use of immunosuppressants was not investi-
gated. On the basis of clinical studies with NSC
transplantation in neurological diseases and earlier
studies in ALS, we think that immunosuppression
should be continued for at least 6 months, at which
point it may be gradually discontinued and stopped
2 years later. A lifelong low daily dose of steroids might
be considered. Moreover, immunosuppressive agents
alone should be studied in a separate patient group.
Immunosuppression must be discontinued in rapidly
deteriorating patients so as not to add drug toxicity
in patients with advanced disease stages.
Informed consent
According to the recommendations of the Interna-
tional Society for Stem Cell Research [23] and previous
phase I/II clinical trials [12,13], informed consent
should be structured as an interview that clearly states
the experimental and preliminary nature of the clin-
ical study and the risks associated with the procedure.
Patients should be aware that the principal aim is in-
creasing the knowledge of the disease.The neurologist
must discuss each question with the patients and their
family. Subjects should be made aware that their par-
ticipation is entirely voluntary and that participation
or nonparticipation would not interfere with their
ongoing clinical care. Before signing, patients and close
relatives should be offered the possibility of meeting
separately with their family physician, the neurosur-
geon and a consultant neurologist, who is not the
neurologist in charge, to discuss all pending issues.
Conclusions
Cell-based therapies may represent a new therapeu-
tic approach for ALS. There is a need to carry out
appropriately designed experimental studies to verify
the long-term safety and possible efficacy of these
therapies. Specific issues with SC-based treatments in-
evitably lead to small trials. In particular, this relates
to the capacity to produce sufficiently large numbers
of standardized cells while meeting safety and quality
standards, the higher risks related to surgical deliv-
ery and the high costs. To accelerate the field of cell
therapy for ALS, we have highlighted some consen-
sus points and recommendations on the basic structure
of phase II/III trials from an international workshop
and identified key translational barriers for further
studies. Given the massive failures of neuroprotective
agents for ALS over the past 20 years, these points
are based, in part, on the lessons learned from prior
failures in the hope of facilitating the successful de-
velopment of cellular therapies for ALS.
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